ALX Oncology Holdings Inc. (ALXO) Misses Q4 EPS by 7c

ALX Oncology Holdings Inc. (NASDAQ: ALXO) reported Q4 EPS of ($0.42), $0.07 worse than the analyst estimate of ($0.35).

For earnings history and earnings-related data on ALX Oncology Holdings Inc. (ALXO) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• NeuroSense posts narrower H1 loss, targets Canada drug filing by December
• Genco Shipping amends shareholder rights agreement, extends to 2027